Management of Superficial Recurrences in an Irradiated Bladder After Combined-Modality Organ-Preserving Therapy

International Journal of Radiation Oncology Biology Physics

Volumn 70, Issue 5, 2008, Pages 1502-1506

  Weiss, Christian ^a   Wittlinger, Michael ^a   Engehausen, Dirk G ^a   Krause, Frens S ^a   Ott, Oliver J ^a   Dunst, Jürgen ^b   Sauer, Rolf ^a   Rödel, Claus ^c  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

Bladder cancer; Cystectomy; Intravesical therapy; Radiochemotherapy; Transurethral resection

Indexed keywords

BIOLOGICAL ORGANS; CHEMOTHERAPY; DISEASE CONTROL; ONCOLOGY; PATIENT MONITORING; RADIOTHERAPY;

BLADDER CANCER; CYSTECTOMY; INTRAVESICAL THERAPY; RADIOCHEMOTHERAPY; TRANSURETHRAL RESECTION;

MEDICAL PROBLEMS;

ANTINEOPLASTIC AGENT; BCG VACCINE; CARBOPLATIN; CISPLATIN; FLUOROURACIL;

ARTICLE; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYSTECTOMY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; IRRADIATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MUSCLE DISEASE; ORGAN PRESERVATION; PRIORITY JOURNAL; SUPERFICIAL CANCER; SURVIVAL RATE; TRANSURETHRAL RESECTION; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL PROTOCOLS; COMBINED MODALITY THERAPY; CYSTECTOMY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY DOSAGE; SURVIVAL RATE; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 40949117575     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.08.007     Document Type: Article

References (12)

1. Rodel C., Weiss C., and Sauer R. Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol 24 (2006) 5536-5544
2. Rodel C., Grabenbauer G.G., Kuhn R., et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: Long-term results. J Clin Oncol 20 (2002) 3061-3071
3. Sylvester R.J., van der Meijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466-465; discussion, 475-467
4. Dunst J., Weigel C., Heynemann H., et al. Preliminary results of simultaneous radiochemotherapy with paclitaxel for urinary bladder cancer. Strahlenther Onkol 175 Suppl. 3 (1999) 7-10
5. Birkenhake S., Leykamm S., Martus P., et al. Concomitant radiochemotherapy with 5-FU and cisplatin for invasive bladder cancer. Acute toxicity and first results. Strahlenther Onkol 175 (1999) 97-101
6. Weiss C., Wolze C., Engehausen D.G., et al. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: An alternative to intravesical therapy or early cystectomy?. J Clin Oncol 24 (2006) 2318-2324
7. Weiss C., Engehausen D.G., Krause F.S., et al. Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys 68 (2007) 1072-1080
8. Manoharan M., and Soloway M.S. Optimal management of the T1G3 bladder cancer. Urol Clin North Am 32 (2005) 133-145
9. Zietman A.L., Grocela J., Zehr E., et al. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: Management and consequences of Ta, T1, and Tis recurrence within the retained bladder. Urology 58 (2001) 380-385
10. Kent E., Sandler H., Montie J., et al. Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: Results of a phase I trial. J Clin Oncol 22 (2004) 2540-2545
11. Muller A.C., Diestelhorst A., Kuhnt T., et al. Organ-sparing treatment of advanced bladder cancer: Paclitaxel as a radiosensitizer. Strahlenther Onkol 183 (2007) 177-183
12. Chakravarti A., Winter K., Wu C.L., et al. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: A report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 62 (2005) 309-317